ClinicalTrials.gg
CompletedNCT05960032Updated Jan 6, 2025Results posted

A Study to Learn About the Study Medicine Called Zavegepant in Healthy Chinese Adult Participants

A Phase 1 interventional study of Zavegepant in Healthy, sponsored by Pfizer. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-06.

Sponsored by Pfizer · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to learn about:

  • how Zavegepant is changed and removed from the body after taken.
  • safety of Zavegepant.
  • the extent to which side effects can be tolerated after taking Zavegepant for the possible short-term treatment of migraine.

This study is seeking participants who:

  • are healthy Chinese adults and includes participants who are between 18 to 55 years old.
  • have body mass index (BMI) of 18 to 30 kg/m\^2.
  • have a total body weight of:
  • equal to or more than 50 kilograms (110 pounds) for males.
  • equal to or more than 45 kilograms (99 pounds) for females.
  • are non-smoker (no use of tobacco or nicotine products).

All participants in this study will receive Zavegepant by nose, once at the study clinic.

The experiences of the participants receiving the study medicine will be looked at. This will help see if the study medicine is safe.

Participants will take part in this study for around 9 weeks. During this time, participants will have 2 study visits at the study clinic and 1 contact over the phone.

02

Conditions studied

  • Healthy

Keywords

  • Zavegepant
  • Healthy volunteer
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Chinese adults and includes participants who are between 18 to 55 years old
  • of 18 to 30 kg/m\^2; and a total body weight ≥50 kg (110 lb) for males and ≥45 kg (99 lb) for females
  • Non-smoker (no use of tobacco or nicotine products).

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of disease.
  • Use of medication other than topical products without significant systemic absorption.
  • Previous participantion in a clinical research study or study prior to the first dosing.
  • Any clinically significant abnormal laboratory test results or positive test.
  • Evidence of organ dysfunction or any clinically significant deviation from normal.
  • Screening supine BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic).
  • Standard 12-lead that demonstrates clinically relevant abnormalities.
  • Abnormalities in clinical laboratory tests: or ALT level > ; Total level > ULN; ANC or ALC level > ULN.
  • Positive urine drug screen, alcohol breath test, or urine cotinine test.
  • Positive pregnancy test.
  • Positive result for COVID-19.
  • History of significant alcohol abuse or drug abuse.
  • History of anaphylaxix reaction or a clinically important reaction to any drug.
  • Donation of plasma within 30 days prior to dosing. Donation or loss of blood of approximately 400 mL or more within 60 days prior to dosing.
  • Inability to be venipunctured and/or tolerate catheter venous access.
  • Habitual use of snuff tobacco.
  • History of sensitivity to heparin or heparin-induced thrombocytopenia.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Zavegepant

    Participants receiving Zavegepant for the treatment phase of the study

    Drug: Zavegepant

Interventions

  • Participants receiving single dose of Zavegepant 10 mg

06

What researchers measure

Primary outcomes

  1. Cmax of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN

    Maximum plasma concentration (Cmax) was measured.

    Time frame: 0 (pre-dose), 5 min, 10 min, 20 min, 30 min, 40 min, 50 min, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours post dose on Day 1

  2. AUClast of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN

    AUClast, area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration (Clast), was measured.

    Time frame: 0 (pre-dose), 5 min, 10 min, 20 min, 30 min, 40 min, 50 min, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours post dose on Day 1

  3. AUCinf of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN

    AUCinf, area under the plasma concentration-time curve from time 0 extrapolated to infinite time, was measured.

    Time frame: 0 (pre-dose), 5 min, 10 min, 20 min, 30 min, 40 min, 50 min, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours post dose on Day 1

Secondary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention, including untoward findings on physical examinations captured as AEs if any.

    Time frame: Day 1 up to maximum of 35 days post single dose administration

  2. Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)

    Time frame: Day 1 up to maximum of 35 days post single dose administration

  3. Number of Participants With Clinically Significant Values of Vital Signs

    Time frame: Day 1 up to maximum of 35 days post single dose administration

  4. Number of Participants With Clinically Significant Values of 12-lead ECGs

    Time frame: Day 1 up to maximum of 35 days post single dose administration

  5. Tmax of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN

    Tmax, time to Cmax, was measured.

    Time frame: 0 (pre-dose), 5 min, 10 min, 20 min, 30 min, 40 min, 50 min, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours post dose on Day 1

  6. t1/2 of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN

    T1/2, terminal half-life, was measured.

    Time frame: 0 (pre-dose), 5 min, 10 min, 20 min, 30 min, 40 min, 50 min, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours post dose on Day 1

  7. CL/F of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN

    CL/F, apparent clearance, was measured.

    Time frame: 0 (pre-dose), 5 min, 10 min, 20 min, 30 min, 40 min, 50 min, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours post dose on Day 1

  8. Vz/F of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN

    Vz/F, apparent volume of distribution, was measured.

    Time frame: 0 (pre-dose), 5 min, 10 min, 20 min, 30 min, 40 min, 50 min, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours post dose on Day 1

07

Results

Posted Jan 6, 2025

Participant flow

A total of 13 participants were enrolled and 12 participants received 1 dose of study intervention, and all 12 participants completed the study.

TREATMENT
Participant flow — TREATMENT
MilestoneZavegepant IN 10 mg
Started12
Received treatment12
Completed12
Not completed0
FOLLOW-UP
Participant flow — FOLLOW-UP
MilestoneZavegepant IN 10 mg
Started12
Completed12
Not completed0

Outcome measures

PrimaryCmax of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN

Maximum plasma concentration (Cmax) was measured.

Time frame:
0 (pre-dose), 5 min, 10 min, 20 min, 30 min, 40 min, 50 min, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours post dose on Day 1
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Cmax of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN
nanogram per milliliter (ng/mL)Zavegepant IN 10 mg
Cmax of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN20.32 ± 114
PrimaryAUClast of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN

AUClast, area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration (Clast), was measured.

Time frame:
0 (pre-dose), 5 min, 10 min, 20 min, 30 min, 40 min, 50 min, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours post dose on Day 1
Reported as:
Geometric mean · ng*hour/mL
AUClast of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN
ng*hour/mLZavegepant IN 10 mg
AUClast of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN44.25 ± 122
PrimaryAUCinf of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN

AUCinf, area under the plasma concentration-time curve from time 0 extrapolated to infinite time, was measured.

Time frame:
0 (pre-dose), 5 min, 10 min, 20 min, 30 min, 40 min, 50 min, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours post dose on Day 1
Reported as:
Geometric mean · ng*hr/mL
AUCinf of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN
ng*hr/mLZavegepant IN 10 mg
AUCinf of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN53.53 ± 128
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention, including untoward findings on physical examinations captured as AEs if any.

Time frame:
Day 1 up to maximum of 35 days post single dose administration
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsZavegepant IN 10 mg
With all-causality TEAEs4
With treatment-related TEAEs3
SecondaryNumber of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)
Time frame:
Day 1 up to maximum of 35 days post single dose administration
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)
ParticipantsZavegepant IN 10 mg
Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)1
SecondaryNumber of Participants With Clinically Significant Values of Vital Signs
Time frame:
Day 1 up to maximum of 35 days post single dose administration
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Values of Vital Signs
ParticipantsZavegepant IN 10 mg
Number of Participants With Clinically Significant Values of Vital Signs0
SecondaryNumber of Participants With Clinically Significant Values of 12-lead ECGs
Time frame:
Day 1 up to maximum of 35 days post single dose administration
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Values of 12-lead ECGs
ParticipantsZavegepant IN 10 mg
Number of Participants With Clinically Significant Values of 12-lead ECGs0
SecondaryTmax of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN

Tmax, time to Cmax, was measured.

Time frame:
0 (pre-dose), 5 min, 10 min, 20 min, 30 min, 40 min, 50 min, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours post dose on Day 1
Reported as:
Median · hour
Tmax of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN
hourZavegepant IN 10 mg
Tmax of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN0.584 (0.333 to 1.00)
Secondaryt1/2 of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN

T1/2, terminal half-life, was measured.

Time frame:
0 (pre-dose), 5 min, 10 min, 20 min, 30 min, 40 min, 50 min, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours post dose on Day 1
Reported as:
Mean · hour
t1/2 of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN
hourZavegepant IN 10 mg
t1/2 of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN11.00 ± 1.4929
SecondaryCL/F of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN

CL/F, apparent clearance, was measured.

Time frame:
0 (pre-dose), 5 min, 10 min, 20 min, 30 min, 40 min, 50 min, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours post dose on Day 1
Reported as:
Geometric mean · Liter/hr
CL/F of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN
Liter/hrZavegepant IN 10 mg
CL/F of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN186.8 ± 128
SecondaryVz/F of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN

Vz/F, apparent volume of distribution, was measured.

Time frame:
0 (pre-dose), 5 min, 10 min, 20 min, 30 min, 40 min, 50 min, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours post dose on Day 1
Reported as:
Geometric mean · Liter
Vz/F of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN
LiterZavegepant IN 10 mg
Vz/F of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN2943 ± 141

Adverse events

Collected over Day 1 up to maximum of 35 days post single dose administration. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zavegepant IN 10 mg0/12 (0%)0/12 (0%)4/12 (33.3%)
Most frequent other events
Most frequent other events
EventZavegepant IN 10 mg
Laryngeal discomfortRespiratory, thoracic and mediastinal disorders1/12
Nasal congestionRespiratory, thoracic and mediastinal disorders1/12
Nasal mucosal discolourationRespiratory, thoracic and mediastinal disorders1/12
Nasal mucosal disorderRespiratory, thoracic and mediastinal disorders1/12
Urticaria papularSkin and subcutaneous tissue disorders1/12

Baseline characteristics

Participants who received study treatments were included in baseline analysis population.

Age, Customized
Age, Customized(Participants)Zavegepant IN 10 mg
<18 Years0
18-25 Years3
26-35 Years6
36-45 Years3
>45 Years0
Sex: Female, Male
Sex: Female, Male(Participants)Zavegepant IN 10 mg
Female4
Male8
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Zavegepant IN 10 mg
Asian12
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Zavegepant IN 10 mg
Not Hispanic or Latino12
08

Study locations

1 site
  • Huashan Hospital,Fudan University
    Shanghai, Shanghai 201107, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Dec 2023, 1 month.

Results were first posted in Jan 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2023
First posted
Jul 25, 2023
StartActual
Oct 23, 2023
Primary completionActual
Dec 12, 2023
CompletionActual
Dec 12, 2023
Results first posted
Jan 6, 2025
Last update
Jan 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05960032
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 25, 2023
Start date
Oct 23, 2023
Primary completion
Dec 12, 2023
Completion
Dec 12, 2023
Results posted
Jan 6, 2025
Last update
Jan 6, 2025

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zavegepant

Start the discussion